Publications by authors named "Timothy B. Lowinger"

Claim this Profile
P
PBPK Modeling to Predict Clinical Drug-Drug Interaction and Impact of Hepatic Impairment for an ADC With the Payload Auristatin F-Hydroxypropylamide.
Niyanta Kumar, Vaishali Dixit, Howard Burt, Katherine L Gill, Hannah M Jones, Timothy B Lowinger

CPT Pharmacometrics Syst Pharmacol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Constructing the cure: engineering the next wave of antibody and cellular immune therapies.
Stefanie R Bailey, Eric Bartee, Kyle G Daniels, Christopher R Heery, Pravin Kaumaya, Timothy B Lowinger

J Immunother Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
X
XMT-2056, a HER2-Directed STING Agonist Antibody-Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells.
Raghida A Bukhalid, Jeremy R Duvall, Kelly Lancaster, Kalli C Catcott, Naniye Malli Cetinbas, Timothy B Lowinger

Clin Cancer Res· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor cell-directed STING agonist antibody-drug conjugates induce type III interferons and anti-tumor innate immune responses.
Naniye Malli Cetinbas, Travis Monnell, Jahna Soomer-James, Pamela Shaw, Kelly Lancaster, Timothy B Lowinger

Nat Commun· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a Novel DNA Mono-alkylator Platform for Antibody-Drug Conjugates.
Joshua D Thomas, Aleksandr V Yurkovetskiy, Mao Yin, Natalya D Bodyak, Shuyi Tang, Timothy B Lowinger

Mol Cancer Ther· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Site-Specific Dolasynthen Antibody-Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios.
Susan M Clardy, Alex Uttard, Bingfan Du, Kalli C Catcott, Kelly L Lancaster, Timothy B Lowinger

Mol Cancer Ther· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer.
Dorin Toader, Shawn P Fessler, Scott D Collins, Patrick R Conlon, Reddy Bollu, Timothy B Lowinger

Mol Cancer Ther· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Optimization of a STING Agonist Platform for Application in Antibody Drug Conjugates.
Jeremy R Duvall, Joshua D Thomas, Raghida A Bukhalid, Kalli C Catcott, Keith W Bentley, Timothy B Lowinger

J Med Chem· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of novel polyamide-pyrrolobenzodiazepine hybrids for antibody-drug conjugates.
Joshua D Thomas, Aleksandr V Yurkovetskiy, Mao Yin, Natalya D Bodyak, Dmitry R Gumerov, Timothy B Lowinger

Bioorg Med Chem Lett· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dolaflexin: A Novel Antibody-Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect.
Aleksandr V Yurkovetskiy, Natalya D Bodyak, Mao Yin, Joshua D Thomas, Susan M Clardy, Timothy B Lowinger

Mol Cancer Ther· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Dolaflexin-based Antibody-Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2b.
Natalya D Bodyak, Rebecca Mosher, Aleksandr V Yurkovetskiy, Mao Yin, Charlie Bu, Timothy B Lowinger

Mol Cancer Ther· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody drug conjugates for treatment of breast cancer: Novel targets and diverse approaches in ADC design.
Pamela A Trail, Gene M Dubowchik, Timothy B Lowinger

Pharmacol Ther· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Polymer-Based Antibody-Vinca Drug Conjugate Platform: Characterization and Preclinical Efficacy.
Alexander V Yurkovetskiy, Mao Yin, Natalya Bodyak, Cheri A Stevenson, Joshua D Thomas, Timothy B Lowinger

Cancer Res· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and antitumor efficacy of XMT-1001, a novel, polymeric topoisomerase I inhibitor, in mice bearing HT-29 human colon carcinoma xenografts.
Mark D Walsh, Suzan K Hanna, Jeremy Sen, Sumit Rawal, Carolina B Cabral, Timothy B Lowinger

Clin Cancer Res· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Naphthol derivatives as TRPV1 inhibitors for the treatment of urinary incontinence.
Klaus Urbahns, Takeshi Yura, Muneto Mogi, Masaomi Tajimi, Hiroshi Fujishima, Timothy B Lowinger

Bioorg Med Chem Lett· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent developments in the discovery of protein kinase inhibitors from the urea class.
Jacques Dumas, Roger A Smith, Timothy B Lowinger

Curr Opin Drug Discov Devel· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and structure-activity relationships of novel IKK-beta inhibitors. Part 2: Improvement of in vitro activity.
Toshiki Murata, Mitsuyuki Shimada, Hiroshi Kadono, Sachiko Sakakibara, Takashi Yoshino, Timothy B Lowinger

Bioorg Med Chem Lett· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and structure-activity relationships of novel IKK-beta inhibitors. Part 3: Orally active anti-inflammatory agents.
Toshiki Murata, Mitsuyuki Shimada, Sachiko Sakakibara, Takashi Yoshino, Tsutomu Masuda, Timothy B Lowinger

Bioorg Med Chem Lett· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Omega-carboxypyridyl substituted ureas as Raf kinase inhibitors: SAR of the amide substituent.
Uday R Khire, Donald Bankston, James Barbosa, David R Brittelli, Yolanda Caringal, Timothy B Lowinger

Bioorg Med Chem Lett· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and discovery of small molecules targeting raf-1 kinase.
Timothy B Lowinger, Bernd Riedl, Jacques Dumas, Roger A Smith

Curr Pharm Des· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of novel and selective IKK-beta serine-threonine protein kinase inhibitors. Part 1.
Toshiki Murata, Mitsuyuki Shimada, Sachiko Sakakibara, Takashi Yoshino, Hiroshi Kadono, Timothy B Lowinger

Bioorg Med Chem Lett· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
trans,anti,trans-Tetra(spirotetrahydrofuranyl)cyclohexane-1,2-dione. Stereocontrolled Synthesis and Definition of Its Susceptibility to Photoisomerization.
Leo A. Paquette, Timothy B. Lowinger, David G. Bolin, Bruce M. Branan

J Org Chem· October 1996

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Definition of Several Control Elements Relevant to the Stereodefined Serial Elaboration of Belted Poly(spirotetrahydrofurans) Fitted with a Cyclohexane Core.
Leo A. Paquette, Marshall Stepanian, Uppuluri V. Mallavadhani, Timothy D. Cutarelli, Timothy B. Lowinger

J Org Chem· October 1996

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis